Skip to content
10-Q

Quarterly Report

Yubo International Biotech Ltd YBGJ

0001640334-26-000912

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 170.42M sh
Shares Diluted Q1 2026 · Mar 31, 2025 119.82M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $6.19K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$207.16K
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$392.04K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $10.38K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$2.3M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$1.95M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.02M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.79M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.02M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.79M
Current Assets Q1 2026 · Mar 31, 2026 $597.82K
Current Assets Q1 2026 · Dec 31, 2025 $667.51K
Total Assets Q1 2026 · Mar 31, 2026 $709.87K
Total Assets Q1 2026 · Dec 31, 2025 $847.1K
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Net Income Q1 2026 · Mar 31, 2026 −$272.61K
Net Income Q1 2026 · Mar 31, 2025 −$435.63K
Operating Income Q1 2026 · Mar 31, 2026 −$289.27K
Operating Income Q1 2026 · Mar 31, 2025 −$467.3K
Gross Profit Q1 2026 · Mar 31, 2026 $0
Gross Profit Q1 2026 · Mar 31, 2025 $0
Cost Of Revenue Q1 2026 · Mar 31, 2026 $0
Cost Of Revenue Q1 2026 · Mar 31, 2025 $0
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0